These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

990 related items for PubMed ID: 24055415

  • 1. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials.
    Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, Dobbs HJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Simmons S, Sydenham MA, Venables K, Bliss JM, Yarnold JR, START Trialists' Group.
    Lancet Oncol; 2013 Oct; 14(11):1086-1094. PubMed ID: 24055415
    [Abstract] [Full Text] [Related]

  • 2. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.
    START Trialists' Group, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM, Brown J, Dewar JA, Dobbs HJ, Haviland JS, Hoskin PJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Morgan DA, Owen JR, Simmons S, Sumo G, Sydenham MA, Venables K, Yarnold JR.
    Lancet Oncol; 2008 Apr; 9(4):331-41. PubMed ID: 18356109
    [Abstract] [Full Text] [Related]

  • 3. One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT.
    Brunt AM, Haviland JS, Wheatley DA, Sydenham MA, Bloomfield DJ, Chan C, Cleator S, Coles CE, Donovan E, Fleming H, Glynn D, Goodman A, Griffin S, Hopwood P, Kirby AM, Kirwan CC, Nabi Z, Patel J, Sawyer E, Somaiah N, Syndikus I, Venables K, Yarnold JR, Bliss JM, FAST-Forward Trial Management Group.
    Health Technol Assess; 2023 Nov; 27(25):1-176. PubMed ID: 37991196
    [Abstract] [Full Text] [Related]

  • 4. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.
    START Trialists' Group, Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bentzen SM, Bliss JM, Brown J, Dewar JA, Dobbs HJ, Haviland JS, Hoskin PJ, Hopwood P, Lawton PA, Magee BJ, Mills J, Morgan DA, Owen JR, Simmons S, Sumo G, Sydenham MA, Venables K, Yarnold JR.
    Lancet; 2008 Mar 29; 371(9618):1098-107. PubMed ID: 18355913
    [Abstract] [Full Text] [Related]

  • 5. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial.
    Murray Brunt A, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, Bloomfield DJ, Chan C, Churn M, Cleator S, Coles CE, Goodman A, Harnett A, Hopwood P, Kirby AM, Kirwan CC, Morris C, Nabi Z, Sawyer E, Somaiah N, Stones L, Syndikus I, Bliss JM, Yarnold JR, FAST-Forward Trial Management Group.
    Lancet; 2020 May 23; 395(10237):1613-1626. PubMed ID: 32580883
    [Abstract] [Full Text] [Related]

  • 6. Comparison of patient-reported breast, arm, and shoulder symptoms and body image after radiotherapy for early breast cancer: 5-year follow-up in the randomised Standardisation of Breast Radiotherapy (START) trials.
    Hopwood P, Haviland JS, Sumo G, Mills J, Bliss JM, Yarnold JR, START Trial Management Group.
    Lancet Oncol; 2010 Mar 23; 11(3):231-40. PubMed ID: 20138809
    [Abstract] [Full Text] [Related]

  • 7. Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial.
    King MT, Link EK, Whelan TJ, Olivotto IA, Kunkler I, Westenberg AH, Gruber G, Schofield P, Chua BH, BIG 3-07/TROG 07.01 trial investigators.
    Lancet Oncol; 2020 May 23; 21(5):685-698. PubMed ID: 32203696
    [Abstract] [Full Text] [Related]

  • 8. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial.
    Coles CE, Griffin CL, Kirby AM, Titley J, Agrawal RK, Alhasso A, Bhattacharya IS, Brunt AM, Ciurlionis L, Chan C, Donovan EM, Emson MA, Harnett AN, Haviland JS, Hopwood P, Jefford ML, Kaggwa R, Sawyer EJ, Syndikus I, Tsang YM, Wheatley DA, Wilcox M, Yarnold JR, Bliss JM, IMPORT Trialists.
    Lancet; 2017 Sep 09; 390(10099):1048-1060. PubMed ID: 28779963
    [Abstract] [Full Text] [Related]

  • 9. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial.
    Kunkler IH, Williams LJ, Jack WJ, Cameron DA, Dixon JM, PRIME II investigators.
    Lancet Oncol; 2015 Mar 09; 16(3):266-73. PubMed ID: 25637340
    [Abstract] [Full Text] [Related]

  • 10. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial.
    Vicini FA, Cecchini RS, White JR, Arthur DW, Julian TB, Rabinovitch RA, Kuske RR, Ganz PA, Parda DS, Scheier MF, Winter KA, Paik S, Kuerer HM, Vallow LA, Pierce LJ, Mamounas EP, McCormick B, Costantino JP, Bear HD, Germain I, Gustafson G, Grossheim L, Petersen IA, Hudes RS, Curran WJ, Bryant JL, Wolmark N.
    Lancet; 2019 Dec 14; 394(10215):2155-2164. PubMed ID: 31813636
    [Abstract] [Full Text] [Related]

  • 11. Dose-escalated simultaneous integrated boost radiotherapy in early breast cancer (IMPORT HIGH): a multicentre, phase 3, non-inferiority, open-label, randomised controlled trial.
    Coles CE, Haviland JS, Kirby AM, Griffin CL, Sydenham MA, Titley JC, Bhattacharya I, Brunt AM, Chan HYC, Donovan EM, Eaton DJ, Emson M, Hopwood P, Jefford ML, Lightowlers SV, Sawyer EJ, Syndikus I, Tsang YM, Twyman NI, Yarnold JR, Bliss JM, IMPORT Trial Management Group.
    Lancet; 2023 Jun 24; 401(10394):2124-2137. PubMed ID: 37302395
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prolongation of overall treatment time as a cause of treatment failure in early breast cancer: An analysis of the UK START (Standardisation of Breast Radiotherapy) trials of radiotherapy fractionation.
    Haviland JS, Bentzen SM, Bliss JM, Yarnold JR, START Trial Management Group.
    Radiother Oncol; 2016 Dec 24; 121(3):420-423. PubMed ID: 27666929
    [Abstract] [Full Text] [Related]

  • 14. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial.
    Owen JR, Ashton A, Bliss JM, Homewood J, Harper C, Hanson J, Haviland J, Bentzen SM, Yarnold JR.
    Lancet Oncol; 2006 Jun 24; 7(6):467-71. PubMed ID: 16750496
    [Abstract] [Full Text] [Related]

  • 15. Postoperative radiotherapy in women with early operable breast cancer (Scottish Breast Conservation Trial): 30-year update of a randomised, controlled, phase 3 trial.
    Williams LJ, Kunkler IH, Taylor KJ, Dunlop J, Piper T, Caldwell J, Jack W, Loane JF, Elder K, Bartlett JMS, Dixon JM, Cameron DA.
    Lancet Oncol; 2024 Sep 24; 25(9):1213-1221. PubMed ID: 39127062
    [Abstract] [Full Text] [Related]

  • 16. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial.
    Whelan TJ, Julian JA, Berrang TS, Kim DH, Germain I, Nichol AM, Akra M, Lavertu S, Germain F, Fyles A, Trotter T, Perera FE, Balkwill S, Chafe S, McGowan T, Muanza T, Beckham WA, Chua BH, Gu CS, Levine MN, Olivotto IA, RAPID Trial Investigators.
    Lancet; 2019 Dec 14; 394(10215):2165-2172. PubMed ID: 31813635
    [Abstract] [Full Text] [Related]

  • 17. Conventional versus hypofractionated postmastectomy proton radiotherapy in the USA (MC1631): a randomised phase 2 trial.
    Mutter RW, Giri S, Fruth BF, Remmes NB, Boughey JC, Harless CA, Ruddy KJ, McGee LA, Afzal A, Gao RW, Shumway DA, Vern-Gross TZ, Villarraga HR, Kenison SL, Kang Y, Wong WW, Stish BJ, Merrell KW, Yan ES, Park SS, Corbin KS, Vargas CE.
    Lancet Oncol; 2023 Oct 14; 24(10):1083-1093. PubMed ID: 37696281
    [Abstract] [Full Text] [Related]

  • 18. Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3-07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study.
    Chua BH, Link EK, Kunkler IH, Whelan TJ, Westenberg AH, Gruber G, Bryant G, Ahern V, Purohit K, Graham PH, Akra M, McArdle O, O'Brien P, Harvey JA, Kirkove C, Maduro JH, Campbell ID, Delaney GP, Martin JD, Vu TTT, Muanza TM, Neal A, Olivotto IA, BIG 3–07/TROG 07.01 trial investigators.
    Lancet; 2022 Aug 06; 400(10350):431-440. PubMed ID: 35934006
    [Abstract] [Full Text] [Related]

  • 19. Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial.
    Velikova G, Williams LJ, Willis S, Dixon JM, Loncaster J, Hatton M, Clarke J, Kunkler IH, Russell NS, MRC SUPREMO trial UK investigators.
    Lancet Oncol; 2018 Nov 06; 19(11):1516-1529. PubMed ID: 30337220
    [Abstract] [Full Text] [Related]

  • 20. Accelerated hypofractionated adjuvant whole breast radiotherapy with concomitant photon boost after conserving surgery for early stage breast cancer: a prospective evaluation on 463 patients.
    Cante D, Rosa La Porta M, Casanova-Borca V, Sciacero P, Girelli G, Pasquino M, Franco P, Ozzello F.
    Breast J; 2011 Nov 06; 17(6):586-93. PubMed ID: 21951485
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 50.